KEYNOTE-716: Long-term follow-up

In this video Prof Dr Jeroen Mebis, medical oncologist at the Jessa Hospital in Hasselt, shares the key take-aways from the updated analysis of the KEYNOTE-716 trial presented at ESMO 2024.

In KEYNOTE-716, 976 patients with surgically resected stage IIB/IIC melanoma were randomly assigned to receive adjuvant pembrolizumab (200 mg q3w) for one year or placebo. The updated results confirm the previously observed significant improvement in recurrence-free (48 months: 71.0% vs. 58.0%; HR[95%CI]: 0.62[0.50-0.78]) and distant metastasis-free survival (58 months: 81.0% vs. 70.0%; HR[95%CI]: 0.59[0.45-0.77]).  with pembrolizumab vs. placebo. The number needed to treat to prevent one recurrence or distant metastasis in this trial was reported at 5.3 and 7.8, respectively.